Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on June 10, 2026. The report addresses a corporate action regarding outstanding common stock warrants issued during a rights offering in July 2024.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity figures. The only specific financial values disclosed relate to the warrant redemption terms:
- Redemption Price: $0.01 per underlying share of common stock.
- Redemption Trigger: Volume weighted average price of common stock equals or exceeds 200% of the exercise price ($22.00 per share) for 20 consecutive trading days.
Material Changes
The Company announced an irrevocable election to redeem the remaining "200% Warrants" (CUSIP # 74587B143) from its 2024 Rights Offering. This action is triggered by the Company's common stock price meeting the specified threshold.
Outlook, Risks, and Unusual Items
Warrant Redemption Timeline:
- Exercise Deadline: Holders may exercise warrants for cash until 5:00 p.m. Eastern Time on July 13, 2026.
- Redemption Date: Any warrants not exercised by the deadline will be redeemed by the Company for $0.01 per warrant share.
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the announcement but does not include additional forward-looking guidance or risk factors beyond the mechanics of the redemption.
Investor Verification Checklist
- Verify the current volume weighted average price of PLSE common stock to confirm the 200% threshold ($22.00) has been met for 20 consecutive trading days.
- Confirm the exact number of outstanding 200% Warrants (CUSIP # 74587B143) to assess potential dilution or cash inflow if exercised.
- Review the attached press release (Exhibit 99.1) for any additional details on the rights offering terms.
- Monitor the stock price between June 10, 2026, and the July 13, 2026, deadline to determine if holders will exercise or let warrants expire.